

Mini review

The orchestrated signaling by PI3K α and PTEN at the membrane interface

Danai Maria Kotzampasi^{a,b,1}, Kyriaki Premeti^{c,1}, Alexandra Papafotika^{d,e,1}, Vasiliki Syropoulou^c, Savvas Christoforidis^{d,e,*,2}, Zoe Cournia^{a,*,2}, George Leondaritis^{c,f,*,2}

^a Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece

^b Department of Biology, University of Crete, Heraklion 71500, Greece

^c Laboratory of Pharmacology, Faculty of Medicine, University of Ioannina, Ioannina 45110, Greece

^d Laboratory of Biological Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece

^e Biomedical Research Institute, Foundation for Research and Technology, Ioannina 45110, Greece

^f Institute of Biosciences, University Research Center of Ioannina, Ioannina 45110, Greece

ARTICLE INFO

Article history:

Received 21 June 2022

Received in revised form 3 October 2022

Accepted 3 October 2022

Available online 7 October 2022

Keywords:

PI3K α

PTEN

Allostery

Membrane trafficking

Phosphoinositides

Membrane-binding

ABSTRACT

The oncogene PI3K α and the tumor suppressor PTEN represent two antagonistic enzymatic activities that regulate the interconversion of the phosphoinositide lipids PI(4,5)P₂ and PI(3,4,5)P₃ in membranes. As such, they are defining components of phosphoinositide-based cellular signaling and membrane trafficking pathways that regulate cell survival, growth, and proliferation, and are often deregulated in cancer. In this review, we highlight aspects of PI3K α and PTEN interplay at the intersection of signaling and membrane trafficking. We also discuss the mechanisms of PI3K α - and PTEN- membrane interaction and catalytic activation, which are fundamental for our understanding of the structural and allosteric implications on signaling at the membrane interface and may aid current efforts in pharmacological targeting of these proteins.

© 2022 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

1. Introduction	5608
2. Overview of PM activation of the PI3K α /Akt/PTEN pathway	5608
3. Phosphoinositide turnover interplay between signaling and membrane trafficking	5608
4. PI3K α and PTEN structure and regulation of membrane interactions	5610
4.1. PI3K α	5610
4.1.1. PI3K α active state	5611
4.1.2. PI3K α membrane interactions	5612
4.2. PTEN	5612
4.2.1. PTEN membrane interactions	5613
4.2.2. The open/closed conformation model of PTEN	5613
5. Allosteric mechanisms for membrane recruitment and catalysis	5614
5.1. Allostery in PI3K α	5614
5.2. Allostery in PTEN	5614
6. Mechanisms for co-regulation of PI3K and PTEN	5615
6.1. Role of p85 α	5615

* Corresponding authors at: Laboratory of Pharmacology, Faculty of Medicine, University of Ioannina, Ioannina 45110, Greece (G. Leondaritis); Laboratory of Biological Chemistry, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece. (S. Christoforidis); Biomedical Research Foundation, Academy of Athens, Athens 11527, Greece (Z. Cournia).

E-mail addresses: schristo@uoi.gr, savvaschristoforidis@bri.forth.gr (S. Christoforidis), zcournia@bioacademy.gr (Z. Cournia), gleondar@uoi.gr (G. Leondaritis).

¹ Equal contribution authors.

² Equal corresponding authors.

<https://doi.org/10.1016/j.csbj.2022.10.007>

2001-0370/© 2022 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

6.2. Localized PI(4,5)P ₂ and PI(3,4,5)P ₃ pools	5615
7. Pharmacological targeting of PI3K α and PTEN	5616
8. Summary and outlook	5616
CRedit authorship contribution statement	5617
Declaration of Competing Interest	5617
Acknowledgements	5617
References	5617

1. Introduction

Eukaryotic cells are defined by the presence of a plasma membrane (PM) and a complex endomembrane system. These membranous compartments exhibit several distinct features that rely on the compartmentalization of specific proteins and membrane lipids and the net charge of the cytosolic face of the membrane bilayer [1]. Amongst these features, relatively non-abundant phospholipids such as phosphoinositides (PIPs) play an essential role in regulating almost all aspects of cell physiology [2,3]. PIPs exhibit a differential subcellular membrane localization, thereby providing a unique PIP code to distinct membrane compartments [4]. These PIP-based switches function as essential drivers of cellular signaling and trafficking at the PM and endomembranes. Phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P₂) and Phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃), specifically, have long been known as defining components of signaling pathways operating under the control of growth factor and neurotransmitter receptors, thus likely constituting the most widespread PIP switch for cellular signaling and membrane trafficking in mammalian cells. One of the major signaling cascades, the PTEN/PI3K α /Akt pathway and more specifically the antagonizing proteins Phosphatidylinositol-3-kinase α (PI3K α) and Phosphatase and tensin homolog (PTEN), regulate cell survival, growth, and proliferation by controlling the interconversion between PI(4,5)P₂ and PI(3,4,5)P₃. In this review, we will highlight the interplay between PI3K α and PTEN in membrane trafficking and signaling, with emphasis on the mechanisms that regulate their membrane association.

2. Overview of PM activation of the PI3K α /Akt/PTEN pathway

Both PI3K α and PTEN are cytosolic proteins that interact transiently with the PM and play pivotal roles in signaling. PI3Ks are critical for initiating the protein kinase B (Akt)/mTOR signaling pathway and play fundamental roles in cell proliferation, growth, metabolism, motility, and intracellular trafficking. Thus, it is not surprising that dysregulation of the PI3K/Akt/mTOR pathway leads to various disorders, including cancer. Specifically, it is the most frequently mutated signaling pathway in human cancer [5]. Phosphoinositide 3-kinases (PI3Ks) are divided into three distinct classes, Class I, II and III. Class I PI3Ks are further classified into four isoforms, α , β , γ and δ , which phosphorylate the hydroxyl group of the inositol ring of phosphatidylinositols at the D-3 position to produce phosphatidylinositol PI(3,4,5)P₃ from PI(4,5)P₂ using ATP (Table 1 for kinetic parameters). Class II PI3Ks, C2 α , C2 β , and C2 γ do not produce PI(3,4,5)P₃, but they primarily synthesize PI(3,4)P₂ with PI(4)P as substrate. The single human class III PI3K, vacuolar protein sorting 34 (hVps34), synthesizes only PI(3)P using PI as substrate [6,7]. PI(3,4,5)P₃ generated by Class I PI3Ks recruits phosphoinositide-dependent kinase-1 (PDK1) and Akt, thus promoting the activation of Akt by PDK1 and mTORC2 phosphorylation [8,9]. The activation of Akt leads to multiple downstream signaling cascades, including the mTOR pathway, which upregulates processes such as transcription and translation, protein synthesis, and cell cycle progression, among others (Fig. 1) [6,10,11]. PIK3CA, the gene that encodes the catalytic subunit of PI3K α is

the most frequently mutated kinase in human malignancies [12], and the second most frequently-mutated oncogene in all human cancers. Activating mutations that are present in many high mortality cancers are located throughout the PI3K α primary sequence [13].

The negative regulator of the pathway is PTEN, thus it may come as no surprise that PTEN is also one of the most frequently mutated tumor suppressors in human cancers. PTEN is recruited to PM and functions as a PI(3,4,5)P₃-phosphatase that dephosphorylates the phosphate at position 3 of the inositol ring and converts PI(3,4,5)P₃ to PI(4,5)P₂, thus directly antagonizing PI3K α [14,15] (Table 1 for kinetic parameters). As a result of low PTEN expression or activity, PI(3,4,5)P₃-downstream signaling pathways are hyper-activated and tumor size increases, while PTEN overexpression brings resistance to tumor growth [14]. Germ-line mutations in the PTEN gene, are associated with several cancer predisposition syndromes, collectively referred to as PTEN Hamartoma-Tumor Syndromes (PHTS) [16]. In addition to its tumor suppressor function, PTEN has an important role in the central nervous system and controls neurogenesis, axonal growth, and synaptogenesis [17].

3. Phosphoinositide turnover interplay between signaling and membrane trafficking

Receptor-mediated signaling initiates upon ligand/receptor interaction at the PM. Extensive studies throughout the last two decades have shown that, soon after receptor activation at the cell surface, ligand/receptor complexes are internalized in PM invaginations, leading to formation of cytoplasmic vesicles that deliver their cargo to the early endosome (reviewed in [25]). At the endosomal compartment, sorting of the ligand/receptor complexes determines whether the receptors will be delivered to the lysosome for degradation, or they will return to the PM for another round of activation. Transport from the endosome to the PM can take place directly (quick recycling), via vesicular carriers budding from the endosomal membrane, or after delivery of the cargo to the recycling endosome, which serves as an intermediate station before further transport of the receptor to the PM (slow recycling) [26]. Interestingly, transport of the ligand/receptor complexes through these intricate endosomal compartments, determines not only the fate of the ligand/receptor complexes, but also the exact transient endomembrane stations where the receptor can activate specific downstream signaling molecules [25]. Thus, the specific endocytic routes undertaken by individual ligand/receptor complexes determine the intensity, duration and output of receptor signaling [27].

This bidirectional interplay between signaling and membrane trafficking, relies on a number of molecular players that are shared between these two processes [28]. Typical molecules of this functional interplay are PIPs. Their regulation by signaling molecules, e.g. receptors [29], and trafficking mediators, e.g. Rab GTPases [30], coordinates receptor-mediated signaling with vesicular transport (Fig. 1). More specifically, clathrin-mediated endocytosis (CME) appears to require the presence of a local pool of PI(4,5)P₂, which is necessary for the initial formation of clathrin coated pits

to endosomes plays an important role in endocytic transport, thereby controlling receptor trafficking and signaling [36].

The Receptor Tyrosine Kinase (RTK)-dependent recruitment of PI3Ks, generation of PI(3,4,5)P₃ from PI(4,5)P₂ and subsequent activation of Akt have been traditionally assigned to take place at the PM. Yet, it is now clear that activation of Akt takes also place at endomembranes [28,37–41]. Interestingly, although PI3K/PI(3,4,5)P₃/Akt signaling can take place both at the PM and intracellularly, different cellular functions appear to depend on activation of this signaling pathway in restricted cellular locations, rather than globally. For example, chemotactic migration of macrophages relies on PM activation of PI3K/Akt [42], while angiogenesis depends on activation of this signaling axis at the endosomes [43,44].

One of the proposed mechanisms for PI3K α -mediated generation of PI(3,4,5)P₃ at the endosomes involves membrane recruitment of the lipid kinase by interaction with the microtubule-binding protein MAP4 [37]. The question that arises from this proposed regulatory mechanism concerns PI(4,5)P₂ availability, which appears to be absent from early endosomes. Thus, according to this mechanism, the *de novo* synthesis of endosomal PI(4,5)P₂ would be required. Batrouni and Baskin hypothesized that phosphorylation of phosphatidylinositol (PI) by PI4KIII α and PIP5K is a possible source of PI(4,5)P₂ [37,45,46]. An additional mechanism that contributes to the production of PI(3,4,5)P₃ at the endosome relies on Rab5-dependent recruitment of the class I PI3K p85 α /p110 β [34], which is also enriched at clathrin coated vesicles [30] (Fig. 1). Subsequently, PI(3,4,5)P₃ is hydrolyzed by 5- and 4- phosphatases, thus contributing to an enrichment of PI(3)P at the endosomal membrane [34]. The presence of class I [34] and class II [47] PI3Ks in endocytic compartments could result in a transient production of PI(3,4,5)P₃, or PI(3,4)P₂, which further supports a local activation of the Akt pathway in the endomembranes [48]. Interestingly, PTEN, besides PI(3,4,5)P₃, dephosphorylates also PI(3,4)P₂ [49,50] and its association with endosomes via a PI(3)P docking site results in termination of endosomal Akt activation [51]. These regulatory mechanisms may ensure that Akt activation is limited to endocytic vesicles that reside in the cell periphery, while mature endosomes that are distant from the PM are restrictive in Akt-signaling. Besides the above mentioned catalytically-mediated role of PTEN at the endosome, endosomal PTEN plays an enzymatically-independent role in Glut1 recycling. More specifically, binding of PTEN to SNX27, an adaptor of various cargo molecules, prevents interaction of SNX27 to VPS26 retromer complex, which disables recycling of GLUT1 to the PM, thus leading to impaired cellular glucose uptake [52]. This PTEN-mediated regulation of glucose metabolism could be part of the PI3K-independent mechanisms that control this metabolic pathway.

Our understanding on the role of endocytosis in receptor signaling and PIP turnover has been greatly facilitated by the development of excellent inhibitors of the various endocytic routes [55–57]. However, as small molecule inhibitors could bind to multiple targets, complementary experiments, e.g. knockdowns or knockouts, are usually undertaken to back up experimental data generated with these inhibitors [58–64].

4. PI3K α and PTEN structure and regulation of membrane interactions

4.1. PI3K α

PI3K α is a heterodimer composed of a catalytic (p110 α) and a regulatory subunit (p85 α), encoded by *PIK3CA* and *PIK3R1*, respectively (Fig. 2a). The catalytic subunit consists of an N-terminal adaptor binding domain (ABD) that mediates binding to the iSH2 domain of p85 α , a Ras binding domain (RBD) that interacts with

switch I and II regions of RAS to stabilize PI3K α on the membrane [65,66], a C2 domain (C2) that participates in membrane binding, a helical domain which interacts with nSH2, and a kinase domain which hosts functionally important regions, including the PI(4,5)P₂ and the ATP binding pockets (Fig. 2a and 2b). *PIK3CA*, the gene encoding the catalytic subunit of PI3K α , is one of the most frequently mutated genes in solid tumors. The vast majority of the oncogenic mutations are located in either one of two hotspots; (i) E545K and E542K located at the interface between nSH2 and helical domain and (ii) H1047R located at C-terminal tail of the kinase domain. The regulatory subunit contains two Src homology 2 domains, nSH2 and cSH2, that bind to the pYXXM motifs of the phosphorylated RTK, and a coiled-coiled domain (iSH2) between them, which mediates the high-affinity interaction to the catalytic subunit. These domains are preceded by a Src homology 3 domain (SH3), a Bar cluster region homology domain (BH), and two proline-rich regions, PR1 and PR2 surrounding the BH domain (Fig. 2a) [6,67]. Cheung et al. reported that SH3 and BH domains along with the PR regions may facilitate the homodimerization of p85 α [68]. Besides p85 α , *PIK3R1* also encodes two functional splice variants, p55 α and p50 α , which lack the domains required for homodimerization (they lack the proline-rich regions, BH and SH3 domains) (Fig. 2c).

Post-translational modifications of p85 α regulate the catalytic activity of PI3K α (Fig. 2d). Direct phosphorylation of S361 in nSH2, and S652 in cSH2, by Protein Kinase C (PKC), prevents PI3K α from binding to the activated receptor [69,70]. It should be noted, however, that PKC α can also indirectly stimulate PI3K/Akt signaling by phosphorylating MARCKS to displace it from PI(4,5)P₂, thereby generating free PI(4,5)P₂, the lipid substrate of PI3K, required for PI(3,4,5)P₃ production [71,72]. Another post-translational modification that prevents the binding of cSH2 to the phosphorylated RTKs is the phosphorylation of S690 in cSH2, by I κ B kinase (IKK). On the contrary, phosphorylation of Y688 in cSH2 may activate PI3K α by facilitating an intramolecular interaction with nSH2. Moreover, phosphorylation of S83 in the SH3 domain by protein kinase A (PKA) promotes p85 binding of 14–3–3 α protein, which leads to increased membrane binding and subsequently to increased p110 α activation [69,70,73]. The catalytic subunit, p110 α can phosphorylate the regulatory subunit, p85 α , at S608, although this autophosphorylation is not a significant regulator of the lipid kinase activity of PI3K α [74]. Moreover, p85 α is phosphorylated on Y508 by the Platelet-derived growth factor receptor (PDGFR) [75]. Cruz-Herrera et al. suggest that SUMO1 and SUMO2 modulate the p85 function by reducing the levels of tyrosine-phosphorylated-p85. Different lysine residues located at the iSH2 domain are putative SUMOylation sites [76].

PI3K α can be activated by phosphorylated RTKs, their adaptor proteins (e.g. IRS-1) and a broad spectrum of RAS family members (e.g. HRAS). RTKs activate PI3K α through binding of the PI3K α SH2 domains to the pTyr residues (pYXXM motifs) located in the cytosolic domain of the activated RTK. This phosphopeptide sequence binds to the nSH2 domain, disrupting the charge-charge interaction between the nSH2 domain and the helical domain of p110 α [6,77]. pTyr also binds to cSH2, however, cSH2 does not have an inhibitory role in PI3K α [78]. Two conserved FLVR motifs (res. 355–358 in nSH2 domain and 646–649 in cSH2 domain) are critical for binding to the phosphorylated RTK [70]. The receptor and the RAS protein synergistically activate PI3K α . In fact, it was shown by Buckles et al. that the activation of PI3K α by RAS is mediated primarily via the membrane recruitment mechanism, rather than allosterically. Thus, the association of receptor pTyr residues with the inhibitory SH2 domains of p85 make p110 accessible for PI(4,5)P₂ and binding of p110 to HRAS contributes to the activation promoting the membrane recruitment [79]. Upon activation, p110 α is recruited to the membrane to syn-




Fig. 2. The structure of the PI3Kα heterodimer and its post-translational modifications. (a) The 3D structure of PI3Kα heterodimer and its domains (b) Functionally important residues of PI3Kα. The 3D structure was produced by authors using PDB ID 7MYN structure as a reference (<https://doi.org/10.2210/pdb7MYN/pdb>) (c) PIK3R1 splice variants. p50α and p55α differ from p85α at N-terminal residues and contain a unique 35-amino-acid and a 5-amino-acid sequence respectively (d) Regulation mediated through post-translational modifications. Phosphorylation sites are represented as yellow circles. PTMs with positive effects on PI3K activity are shown with arrows, whereas those with negative effects on PI3Kα activity are shown with bars. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

thesize PI(3,4,5)P₃ by transferring the γ-phosphate group of ATP to PI(4,5)P₂.

However, the ATP pocket (active site) and the PI(4,5)P₂ binding site of PI3Kα are 6–7 Å apart in crystal structures of the inactive state (e.g. PDB ID: 4OVV [80]). For the phosphorylation to take place, PI(4,5)P₂ needs to approach ATP. This is mediated through a sequence of allosteric motions that are triggered by nSH2 disengagement. Hence, the surface of the kinase domain becomes accessible for interaction with the membrane [81].

4.1.1. PI3Kα active state

The natural transition of PI3Kα from an inactive cytosolic state to an activated state on membranes entails four distinct events. Apart from the breaking of the nSH2–helical interface described

above (event 1), three other events have been described by Burke et al. [82]. These events include disrupting the iSH2–C2 interface (event 2), movement of the ABD domain relative to the kinase domain (event 3), and interaction of the kinase domain with the membrane (event 4). Based on HDX-MS data and protein-lipid FRET assays, oncogenic mutations upregulate the enzyme by enhancing one or more of these dynamic events [82]. Moreover, a recent cryo-electron microscopy (cryo-EM) study showed that the phosphopeptide-bound structure of PI3Kα consists of a stable core, where electron density for ABD and the regulatory subunit is absent (Fig. 3a) [83]. Indeed, in a previous study Zhao et al. had shown that the deletion mutant of PI3Kα lacking the ABD domain (ΔABD) and the entire regulatory subunit, efficiently activates PI3K signaling [84].




Fig. 3. The active state of PI3K α and its membrane-interacting regions. The 3D structure was produced by authors using PDB ID 7MYN structure as a reference [83] (a) Proposed active state model of PI3K α in which electron density for the ABD and the p85 α is absent (b) The Δ ABD model on a model cell membrane based on the PDB ID 7MYN structure [83]. Membrane interacting residues are colored green. (c) Residues 405–420 of the nSH2 domain (colored red) are in close proximity to the membrane. The Δ ABD model based on the 7MYN structure is colored blue and the superimposed Δ ABD + nSH2 structure of the E545K mutant with a detached nSH2 domain, as observed in our simulations, is colored green. The Δ ABD model was placed on a model membrane at a distance of 5 Å and was rotated to match the referred membrane interactions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

4.1.2. PI3K α membrane interactions

As mentioned, mutations are distributed throughout the primary sequence with two main hot spots in key regulatory regions, one in the helical domain (E545K) and one in the C-terminus of the kinase domain (H1047R). The PI3K α C-terminus plays both an auto-inhibitory role for the kinase, but is also a key element for binding to the cell membrane, where PI3K α receives its substrate, the lipid PI(4,5)P₂, and converts it to PI(3,4,5)P₃, which starts a signaling cascade for cell proliferation. It has been shown in the literature that PI3K α C-terminal mutants such as the H1047R prevalent PI3K α mutation cause the kinase to be overactivated by altering the PI3K α interaction with the cell membrane [82,85–87]. According to HDX-MS data of the overactivated H1047R oncogenic mutant, the membrane-binding regions are 716–744 (membrane binding loop1), 848–859 (active site), 859–872 (membrane binding loop 2), 930–956 (activation loop) and 1039–1068 (C-terminus) (Fig. 3b) [82,88,89]. To generate a model of the PI3K α active state we used the recent cryo-EM structure with PDB ID: 7MYN [83] the model of Δ ABD p110 α . Taking into account the above-mentioned membrane-binding regions, the Δ ABD model was appropriately placed on a model cell membrane. Additionally, we aligned this Δ ABD model with a representative conformation of the E545K mutant from our previous simulations, in which the nSH2 domain has detached from the helical domain [90] mimicking the active state. We find that the region 405–420 of the nSH2 domain is in close proximity to the membrane (Fig. 3c). Indeed,

HDX-MS experiments show that the 405–420 region of nSH2 exhibits decreased hydrogen–deuterium exchange upon membrane binding with HRAS-coupled vesicles, suggesting that nSH2 binds not only to the RTKs but also to the membrane [89,91]. Full activation of PI3K α requires recruitment to membrane-bound HRAS, which greatly leads to the formation of a stable, membrane-bound PI3K α complex [79].

4.2. PTEN

PTEN is a cytosolic 403aa protein consisting of five functional domains. The N-terminus contains the PI(4,5)P₂-binding domain (PBD), which folds into an α -helix conformation [92–94], the catalytic phosphatase domain, which includes the active site composed by the P loop with the catalytic CX5R sequence, the WPD loop, the TI loop, and a positively charged Arginine loop [94–97], the C2 domain, which contains CBR1, CBR2 and CBR3 loops that are responsible for PTEN binding to the membrane [94–96,98] and the C-terminal tail (CTT), which is crucial for PTEN regulation [99,100]. At the end of the CTT a PDZ-binding region is located, which facilitates the interaction with other proteins [17,101] (Fig. 4a).

PTEN is under hierarchical control by transcriptional, post-transcriptional and post-translational mechanisms, and protein–protein interactions [14]. Post-translational modifications are heavily studied and include phosphorylation [102], oxidation




Fig. 4. The structure of PTEN and phosphorylation sites on CTT. (a) The domains and functionally important residues of PTEN (b) PTEN on a model cell membrane. Domains and regions that interact with the membrane are colored green (actual interacting residues are given in the text). The 3D structure was produced by authors using PDB ID 5BZZ structure as a reference [128] (c) Schematic illustration of PTEN membrane localization and conformation. The open/closed PTEN model. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

[103], acetylation [104] and ubiquitination [105] amongst others (reviewed in [14,106]. Phosphorylation is the major determinant of PTEN conformations with residues S380, T382, T383 and S385 in the CTT phosphorylated by CK2 *in vitro* [107], and likely by additional kinases *in vivo* [102,108,109]. Residues T366 and S370 are phosphorylated by GSK3 β and CK2, respectively [110], and they may be important for stability and active-site accessibility of PTEN [111,112]. Ubiquitination is also an important posttranslational modification that controls both stability of PTEN and its shuttling to the nucleus [14,106].

The PTEN crystal structure has been reported early on [94], providing significant insight into its regulatory mechanisms. However, some unstructured intrinsically disordered regions (IDRs) were missing or incomplete, like the CBR3 loop, the CTT and the N-terminus [94,113]. Importantly, and in contrast to PI3Ks, PTEN appears to constitutively and dynamically interact with membranes via multiple interactions of its domains depending on the lipid composition of the membranes [17,98,114].

4.2.1. PTEN membrane interactions

According to HDX-MS data of the active dephosphorylated PTEN in the presence and absence of cholesterol and PI(4,5)P₂-containing lipid vesicles the membrane-interacting regions are residues, 4–21, 35–42 (Arginine loop), 82–99 (WPD loop), 155–177 (TI loop), 201–215 (CBR1 loop), 259–273 (CBR3 loop), 319–342 (Ca2) (Fig. 4b) [96]. The WPD and TI loops, together with the P loop, create a negatively charged, wide and deep pocket, allowing access to the bulky PI(3,4,5)P₃ in the membrane [94]. From functional mutagenesis studies the dominant PTEN membrane binding sites include: (a) the C-terminus of the PBD α -helix and the N-terminus of the phosphatase domain that interact with PI(4,5)P₂ with residue K13 being required for binding [93,115]; (b) the positively charged Arginine loop in the phosphatase domain that boosts the interaction with acidic phospholipids including PI (3,4,5)P₃ [96,97,114]; (c) the CBR3 and Ca2 loops in the C2 domain that bind to both zwitterionic and anionic membrane phospholipids [92,116]. Interestingly, molecular dynamics simulation of

the phosphatase-C2 domains of PTEN suggests that binding to the membrane proceeds through electrostatic interactions and results in changes in the relative orientation of the phosphatase and C2 domain [117].

4.2.2. The open/closed conformation model of PTEN

A breakthrough in our understanding of the membrane-associated PTEN active state has been the discovery that PTEN can assume two conformations: an “open” (active) and a “closed” (inactive) state (Fig. 4b). When S380, T382, T383, and S385 of the CTT are phosphorylated, PTEN assumes the compact “closed” state with reduced membrane interaction and phosphatase activity [96,118]. The closed state is associated with increased stability and it is strengthened by intramolecular interactions between the phosphorylated CTT that folds over the active-site and the C2 domain [22,118,119]. Chen et al using X-ray scattering, found that phosphorylated C-tail interacted with the Ca2 and CBR3 loops of the C2 domain but also with the Arginine loop of the phosphatase domain [120]. These results are in agreement with Masson et al. 2016 mass spectrometry (HDX-MS) experiments [96] and also compatible with crystallography studies on semisynthetic PTEN-like molecules [121]. Residues R41, E73, N262, and N329 in the phosphatase and C2 domains play important roles in the intramolecular interaction with the CTT and specific mutations in these residues result in increased membrane association and increased phosphatase activity of PTEN [122].

Thus, phosphorylated PTEN assumes a “closed” autoinhibited form that is mostly cytoplasmic, whereas upon dephosphorylation of the CTT, the autoinhibition is released, the active site is exposed, thus permitting access to PI(3,4,5)P₃ in the membrane [123]. Apparently, the released unphosphorylated CTT does not interact with membranes nor interfere with PTEN membrane binding per se [114,116]. Mutation of S/T residues in the 380–385 stretch of CTT to alanine results in an “open” PTEN conformation, localized at the membrane with increased catalytic activity [105]. The details of how this phosphorylation-induced conformational changes happen are missing and the fact that PTEN CTT is consid-

ered an IDR, makes it difficult to create an accurate structural model of the proposed closed state [112,121,124,125]. While several kinases, most prominently CK2, have been postulated to phosphorylate PTEN and thus induce the conformational shift to the autoinhibited state [126], the involvement of protein phosphatases has been understudied. In this context, it has been suggested that PTEN may release this auto-inhibitory state by its protein phosphatase activity. Although this notion is compelling, and it is supported by some experimental data [111,127] very little is known about the mechanism of this regulatory step.

It has been proposed that formation of PTEN dimers is an additional step towards its full activation [129,130]. Homodimerized PTEN is in the open conformation and exhibits maximal lipid phosphatase activity [129]. PTEN dimers seem to assume a more compact conformation than monomers, and the CTT is highly associated with the stability of the configuration. This compact conformation permits increased cooperativity between the catalytic and C2 domains that may affect the efficiency of the phosphatase activity [130]. The biological significance of PTEN dimer formation has been demonstrated *in vitro* and *in vivo*; it has been proposed that mutated PTEN alleles have a dominant negative function on the wild type protein via dimer formation [129]. Dimerization appears to be inhibited by the E3 ligase WWP1 via K27-linked polyubiquitination of PTEN [131]. Accordingly, pharmacological inactivation of WWP1 reactivates PTEN and suppresses PI3K/Akt-dependent tumorigenesis [131].

5. Allosteric mechanisms for membrane recruitment and catalysis

The conformational landscape of a protein is defined by pre-existing protein conformations that interconvert as a result of ligand/co-factor/protein binding, membrane encounter, and other environmental factors. The shift of the equilibrium protein populations due to a perturbation on the protein, which biases the conformations towards specific conformers is defined as allostery. As such, allostery can be viewed as an intrinsic property of the conformational ensemble and not simply an induced fit phenomenon. Allostery has been highlighted as an important aspect of protein-membrane interactions during signaling [132] and furthermore, provides an innovative approach to modulate protein function by biasing protein structure towards specific active or inactive conformations. Therefore, describing the protein conformational ensemble is of paramount importance as these protein conformations can be stabilized by allosteric modulators. Allosteric modulators typically bind to less conserved sites compared to the active site of an enzyme, and consequently they may confer greater specificity in mutant proteins compared to the WT, or selectively target a specific isoform within a protein family [133]. Below, we briefly discuss current knowledge on the allosteric modes of PI3K α and PTEN interaction with membranes and catalytic activation.

5.1. Allostery in PI3K α

The full molecular mechanism of how PI3K α binds on the membrane and becomes activated is still unclear. As mentioned above, the nSH2 disengagement leads to the activation of PI3K α triggering a series of allosteric conformational changes. In the inactivated conformation of PI3K α , nSH2 interacts with the C2, helical and kinase domains [85]. Upon nSH2 binding to the RTK, these interactions are no longer present. The interface between nSH2 and the helical domain, which includes charge interactions between the negatively-charged helical domain and the positively-charged nSH2 becomes disrupted. The nSH2 release partially destabilizes

the iSH2-C2 and ABD-Kinase interfaces revealing its inhibitory role [82,88,134].

Conformational changes in the iSH2-C2 interface and the ABD/RBD linker may be mechanistically linked according to HDX-MS data. Burke et al. observed that mutations in the ABD-RBD linker caused similar conformational changes to those located at the iSH2-C2 interface [82].

Mutations in the C-terminal tail may also influence the allosteric regulation of enzyme activity, lipid binding, phosphoryl-transfer or product release during catalysis [6]. The hotspot H1047R mutation alters the membrane recruitment as it leads to a large rearrangement of the membrane-binding C-terminus to an active conformation. Mandelker et al. reported the crystal structure of the mutated heterodimer and observed that R1047 points toward the cell membrane, perpendicular to the orientation of H1047 in the WT enzyme [85]. Also, the performed biochemical assays revealed that the enzymatic activity of the p110 α H1047R mutant is differentially regulated by lipid membrane composition [85]. Hon et al. report that the activated H1047L, H1047R and G1049R mutants increase both hydrophobic and electrostatic interactions with lipids [135]. Moreover, Burke et al. using hydrogen/deuterium HDX-MS and protein-lipid FRET assays showed that mutations such as H1047R favor the membrane interaction [82]. Gkeka et al. proposed a series of events that lead to the overactivation of the protein kinase mutant H1047R, using SPR experiments and Molecular Dynamics (MD) simulations [86]. The proposed mechanism of overactivation due to the H1047R PI3K α mutant, includes enhanced binding of H1047R to the membrane, loss of the C-terminal autoinhibitory role and orientation change of H917, a residue critical for ATP hydrolysis. Dynamical Network analyses performed on PI3K α WT and H1047R mutant trajectories [86] showed that the C-terminal tail of PI3K α is connected to the PI3K α membrane binding loop 2 through a pathway of ten residues, whereas the mutant H1047R significantly shortens this path to a pathway of six residues [132]. Recently, Ranga-Prasad et al. suggested that the recruitment and activation of PI3K α to the membrane triggers the release of the ABD domain from p110 α , of the iSH2 from the C2, and also requires the reorientation of the C-terminal tail [88].

Except for the nSH2 domain, another interesting element of p85 α involved in PI3K α activation is the third helix of the iSH2 domain, α 3 (res. 587–598). This helix forms an interface with the activation loop and is expected to stabilize it in the inactive conformation of PI3K α [80]. Simulations performed by Galdadas et al. have shown that the disruption of the interactions between the α 3 helix and the activation loop along with the bending of the N-terminal part of the iSH2, expose helix A to the solvent weakening the nSH2 domains-mediated regulation of the kinase activity, which is in accordance with HDX-MS experiments [78,80,82].

5.2. Allostery in PTEN

An important aspect in order to appreciate allosteric regulation of PTEN relies on its mode of interfacial catalysis kinetics. PTEN likely operates via a mixed scooting/hopping model [24,114]. PI (4,5)P₂, the product of PTEN, appears to be a major determinant of catalytic activation by imposing a positive feedback loop upon interaction with membranes. Early studies showed that catalytic activity is stimulated by 5–8fold when assayed with lipid vesicles containing variable amounts of PI(4,5)P₂ [24,115]. Interestingly, this PI(4,5)P₂-dependent increase of catalytic activity is observed also with monodispersed PIPs, which are typically water-soluble, suggesting that interaction with membrane per se is not the decisive factor [136]. At higher PI(3,4,5)P₃ concentrations the kinetic curves are sigmoidal and do not follow Michaelis-Menten models.

This indicates that enzymatic activity increases as the reaction progresses, apparently due to the increase of its product, $\text{PI}(4,5)\text{P}_2$ [136]. Furthermore, $\text{PI}(4,5)\text{P}_2$ may additionally regulate the membrane lateral diffusion of PTEN. Thus, individual PTEN molecules may exhibit temporal changes in their lateral diffusion mobility as the local $\text{PI}(4,5)\text{P}_2$ density changes on the membrane whereas the spatial distribution of $\text{PI}(4,5)\text{P}_2$ also changes depending on the local density of PTEN, since $\text{PI}(4,5)\text{P}_2$ density increases due to the enzymatic activity [137]. These findings imply multiple feedback loop mechanisms operating at the level of membrane between PTEN and $\text{PI}(4,5)\text{P}_2$.

Detailed analysis using supported lipid bilayers coupled to TIRF imaging has proposed that PTEN kinetics can be described by a combination of both recruitment and allosteric activation effects by $\text{PI}(4,5)\text{P}_2$ [138]. Interestingly, this $\text{PI}(4,5)\text{P}_2$ positive feedback loop is necessary and sufficient for the reaction size-dependency of PTEN catalysis that is readily observed in restricted supported lipid bilayers [139].

Recent studies have updated and informed the open-closed conformation notion and the allosteric $\text{PI}(4,5)\text{P}_2$ positive feedback loop notion [116,121]. The temporal sequence of allosteric modes embedded in the activation of PTEN and the interaction with membrane are: (a) phosphorylation of the CTT (S380, T382, T383, S385 stretch) results in intramolecular closure with CTT contacting the CBR3 loop and C α 2 segment in C2 domain and likely extending into the phosphatase domain; at the same time this closure disrupts the N-terminal α -helix of PBD [121]. (b) dephosphorylation of PTEN results in the open conformation which uncovers the active site in the phosphatase domain and regains the α -helical motif in PBD. (c) binding to the membrane proceeds via the positively charged arginine loop and CBR3 loop in the phosphatase and C2 domains respectively [116]. (d) the initial PBD α -helical motif is rapidly disrupted and converted into an unstructured region which anchors the protein in the lipid bilayer via strong salt bridge interactions between anionic lipids and a polybasic patch (R11, K13, R14, and R15), resulting in the coordination of two $\text{PI}(4,5)\text{P}_2$ lipids [116]. It is likely that the coordination of $\text{PI}(3,4,5)\text{P}_3$ to the P loop may allosterically promote PBD unfolding to stabilize PTEN binding to the membrane [116].

6. Mechanisms for co-regulation of PI3K and PTEN

Although PI3K α and PTEN have been studied extensively, due to their importance in diseases including cancer, there are still significant gaps in our understanding of how these two proteins co-regulate and orchestrate interconversion of $\text{PI}(3,4,5)\text{P}_3$ and $\text{PI}(4,5)\text{P}_2$. Both are cytosolic proteins, which implies that their recruitment on the membrane plays a fundamental role in their mechanism of action. Although membrane recruitment and catalytic activation of PI3K α is agonist-induced and receptor-operated, this is not the case for PTEN. Several receptors of the tyrosine kinase and G protein-coupled receptor families have been proposed to bind and recruit PTEN to the PM although it is not always clear if these interactions are direct or even agonist-induced [17,106]. Regardless, these interactions may function to prime PTEN towards PI3K-generated $\text{PI}(3,4,5)\text{P}_3$ domains [17]. It has to be emphasized that although recruitment and activation of PTEN to sites of PI3K/ $\text{PI}(3,4,5)\text{P}_3$ signaling may be important for fine tuning of $\text{PI}(3,4,5)\text{P}_3$, it may be counterproductive in other settings, particularly when a polarized steep $\text{PI}(3,4,5)\text{P}_3$ distribution on the PM is necessary for cell functions. For example, PTEN may be still recruited but inhibited at the PM in order to attain high levels of $\text{PI}(3,4,5)\text{P}_3$, for induction of filopodia and branches along neuronal axons [140,141], or even actively excluded from PM regions with intense synthesis of $\text{PI}(3,4,5)\text{P}_3$ to ensure continuous

and robust cell polarization and chemotaxis [142,143]. Below we briefly discuss different modes of interaction and co-regulation of PI3K and PTEN.

6.1. Role of p85 α

It has been reported that p85 plays a dual function in regulation of $\text{PI}(3,4,5)\text{P}_3$ upon growth factor receptor activation. In addition to its role as a regulatory subunit of p110-PI3Ks, p85 α binds directly to unphosphorylated PTEN and enhances its stability and phosphatase activity [144,145]. Consequently, p85 α would be an ideal candidate for the temporal co-regulation of PI3K and PTEN activities towards $\text{PI}(4,5)\text{P}_2$ and $\text{PI}(3,4,5)\text{P}_3$ upon acute signaling. Binding proceeds via interactions of the BH domain of p85 with the phosphatase and C2 domains of PTEN [146]. Interestingly, the BH domain of p85 α binds with low affinity to monophosphorylated PIPs *in vitro*; the binding to $\text{PI}(3)\text{P}$ specifically [146], might also help to localize p85 α to endosomal vesicles containing PTEN [51]. Cancer-related mutations in the p85 α -BH domain, however, do not consistently correlate with changes in PTEN activity [147]. Cheung et al. have suggested that p85 α dimers bind and stabilize PTEN by preventing ubiquitination and degradation by the E3 ligase WWP2 [68]. The p85 α homodimer includes intermolecular interactions between SH3:PR1 in trans and BH:BH interactions between the monomers. The homodimerized p85 α binds PTEN at least partly through the PR2 domain and through several residues of the BH domain (I127, I133, E137) [68].

This model of dual regulation of p110 α and PTEN entails the presence of free p85 α in the cytoplasm that is able to either form homodimers, or stabilize and activate p110 α and PTEN. The presence of excess free p85 α has been verified and indeed it modulates PI3K signaling with the effect being dominant at low levels of receptor activation [148]. Also, the balance between the amount of p85 α and the amount of the splice variants, p50 α and p55 α , which are not able to stabilize p110 α as strongly as p85 α and at the same time cannot form homodimers, can affect PI3K α signaling. Although the direct regulation of PTEN by free p85 in the monomeric or dimeric form provides an intriguing explanation for the known effects of partial loss of p85 α on PI3K signaling, these results have not been verified by other groups [149]. Thorpe et al. have suggested that PTEN downregulation may represent a secondary (and not a direct) effect of p85 α loss [149]. It is likely, however, that direct p85 α -PTEN interactions might play an important role under certain conditions for example in specific cell types or specific growth factor receptors.

6.2. Localized $\text{PI}(4,5)\text{P}_2$ and $\text{PI}(3,4,5)\text{P}_3$ pools

Intriguingly, recent advances in lipid kinase and phosphatase assays on restricted supported bilayer systems have revealed a reaction size-dependency of catalytic activity of several enzymes, including PTEN [139,150]. In essence, reaction size-dependency of PTEN suggests that PTEN will dephosphorylate faster large domains of $\text{PI}(3,4,5)\text{P}_3$ compared to small domains on the PM. Studies with $\text{PI}(4,5)\text{P}_2$ phosphatase and $\text{PI}(4)\text{P}$ kinase pairs have shown that competition may result in formation of a compositional pattern of $\text{PI}(4)\text{P}$ and $\text{PI}(4,5)\text{P}_2$ that exhibits bistability when the membrane reaction environment is geometrically confined [150]. This model has been also proposed for PI3K and PTEN competition, thus imposing size-restriction and bistability to $\text{PI}(3,4,5)\text{P}_3$ and $\text{PI}(4,5)\text{P}_2$. [139,150].

These fundamental properties of antagonizing lipid kinases and phosphatases may relate also to the distribution of PIP-rich domains in the PM. Recent super resolution microscopy of $\text{PI}(4,5)\text{P}_2$ and $\text{PI}(3,4,5)\text{P}_3$ in live cells or membrane sheets have advanced our understanding of the segregation, fractional partitioning and

distinct properties of PI3K domains in the membrane. For example, PI(4,5)P₂ and PI(3,4,5)P₃ appear to mark distinct nanoscale domains within the PM of PC12 cells under basal conditions [151]. PI(4,5)P₂ has been observed in nanoscale domains within the PM in several experimental settings (reviewed in [152]). Considering the biophysical properties of distinct PI(4,5)P₂ domains, these may correspond to liquid-ordered, cholesterol-rich “raft-like” or liquid-disordered “non-raft” regions of the membrane [152]. Interestingly, raft and non-raft PI(4,5)P₂ domains may experience differential dynamics upon receptor activation of Phospholipase C signaling [153]. The spatial segregation, recruitment and signaling of PI3K and PTEN in lipid raft vs non-lipid raft membranes has also been proposed [154], with PTEN primarily localized in non-raft domains. This segregation, however, may relate to the activation of PI3Kβ isoform in lipid rafts rather than the PI3Kα isoform [155].

Although intuitively one assumes that PI3K and PTEN are co-regulating the same PI(3,4,5)P₃ domains in the PM, we still lack the temporal and spatial insight on whether this is indeed the case. Paradoxically, in chemoattractant-induced migration of Dictyostelium slime molds and immune cells, PTEN and PI(3,4,5)P₃ exhibit mutually exclusive localization at the PM [142,143]. This segregation corresponds to PI(3,4,5)P₃-enriched/PTEN-excluded and PTEN-enriched/PI(4,5)P₂-rich but PI(3,4,5)P₃-excluded states. This apparent segregation suggests that, at least upon strong activation of PI3Ks, PTEN may be actively excluded from PI(3,4,5)P₃-rich PM regions [143].

7. Pharmacological targeting of PI3Kα and PTEN

PI3Kα has emerged as a promising therapeutic target due to its importance in cancer. Extensive efforts have been made in the last decades to develop drugs able to regulate PI3Kα signaling. Inhibitors targeting PI3Kα can be classified into pan-PI3K, dual PI3K/mTOR and isoform-specific inhibitors. Pan-PI3K inhibitors are ATP-competitive inhibitors that target all four isoforms of class I PI3K and thus, due to their non-selectivity, are associated with several adverse reactions. An example of a pan-PI3K inhibitor is Copanlisib, which is FDA-approved for treatment of adult patients with relapsed follicular lymphoma [156]. Dual PI3K/mTOR inhibitors target and block both all PI3K isoforms and mTOR kinase. They exhibit poor tolerance when given systemically and therefore none of them has been approved by the FDA [157,158]. Isoform-specific PI3K inhibitors selectively inhibit specific PI3K isoforms and four FDA-approved isoform-specific inhibitors are currently on the market; Alpelisib, which is selective against PI3Kα [159], Idelalisib [160] and Umbralisib selective against PI3Kδ [161] and Duvelisib, which is a dual PI3Kγ/PI3Kδ inhibitor [162]. Although the development of PI3K inhibitors has progressed rapidly with many drugs entering clinical trials in the last few years, intrinsic and acquired resistance limits their therapeutic efficacy [163]. Resistance to PI3K inhibitors often occurs through numerous feedback loops involved in the PI3K/Akt signaling network, rebalancing the inhibitory effects of the drugs [158]. Other factors that can lead to resistance in PI3K inhibitors include inactivation or loss of PTEN activity [164], mutations and amplification of PI3K [165], and non-coding RNAs (ncRNAs) [166].

As mentioned, only one PI3Kα-targeting drug is currently in the clinic, alpelisib, which has been approved by the FDA for breast cancer due to its selectivity and pharmacokinetics [159]. Another orthosteric small molecule PI3Kα inhibitor, Inavolisib (GDC-0077), leads to degradation of the E545K and H1047R mutant p110α in cells [167] and is in clinical trials [168]. Both these ATP-competitive inhibitors exhibit severe concentration-dependent adverse effects due to the fact that the ATP binding

pocket is very similar across the different PI3K isoforms [169]. Understanding the allosteric pathways that exist in PI3Kα and its mechanism of action (see Section 5.1) will enable the design of mutant-specific inhibitors that will selectively regulate the membrane-binding and activation. Targeting the protein-membrane interface emerges as a new promising therapeutic strategy, as the activation of PI3Kα is directly linked to the membrane recruitment. The membrane-binding regions are expected to communicate with the active site and thus it can be modulated allosterically.

In contrast to PI3Kα, less attention has been given to development of effective drugs that modify the activity of PTEN, likely because it is considered undruggable [116,125]. However, positive or negative modulators of PTEN may find use in cancer and neurodevelopmental diseases or neurodegenerative and nerve injury conditions, respectively [170]. Unfortunately, currently used 1st generation PTEN inhibitors suffer from specificity, selectivity and reversibility issues [171] and unexpected adverse effects (Premeti, Syropoulou, Leondaritis, unpublished data). Most 1st generation PTEN inhibitors are complexes of peroxy-V (V), oxo-V (VI) and vanadyl- (VO-) with organic substituent, and they are proposed to cause oxidative inhibition of PTEN, at least *in vitro* [128,171,172]. However, it is unclear whether all these compounds act by oxidative inhibition in cells (Premeti, Syropoulou, Leondaritis, unpublished data). Nevertheless, some of these compounds have exhibited promising results in preclinical animal studies assessing tissue survival and regeneration after trauma [173].

As previously discussed, the interaction with the membrane has a crucial role for enzymatic activity of PTEN [116,174]. Considering the allosteric mechanisms that affect PTEN membrane interaction and catalytic activation (see Section 5.2), could we design reversible allosteric modifiers/modulators to shift the equilibrium between active and inactive states or influence the formation of dimers [116,125]? Recently, PTEN reactivation by small molecules that restore its dimerization via inhibition of polyubiquitination has proved the validity of these approaches to treat cancer [131]. In alternative approaches, peptides targeting several regions and domains of PTEN have proven their validity in modulating (inhibiting) PTEN membrane interactions and activity in neurodegenerative and nerve injury conditions [175,176]. On a more general note, direct PTEN modulators will certainly provide us with unprecedented insight on the acute roles of PTEN upon activation of PI3K signaling; so far, we have almost exclusively relied on genetic means of manipulating PTEN activity or localization to membrane.

Although controlling PI3K signaling through PTEN activity is crucial for the regulation of vital cellular mechanisms, the function of PTEN as a tumor suppressor gene complicates the use of existing drugs as well as the design of new potential modulators. Considering PTEN's association with a multitude of other diseases and pathological phenotypes beyond cancer, it is increasingly recognized that we need to better study and understand the complications and benefits of PTEN's pharmacological targeting.

8. Summary and outlook

As described herein, our knowledge of the mechanistic and structural details of PI3Kα and PTEN membrane interactions and catalytic activation have progressed at a rapid pace over the last decade. However, the molecular mechanisms of how PI3Kα and PTEN communicate and co-regulate remain unclear. Thus, we lack fundamental insight into how they antagonize, or even synergize, to create spatially and temporally dynamic pools of signaling PI(3,4,5)P₃ in the rich PI(4,5)P₂ environment of the PM inner leaflet. Do PI3Kα and PTEN display bistability upon competition on mem-

branes as has been suggested for other pairs of PIP kinases and phosphatases [150]? What is the role of PI(4,5)P₂ or PI(3,4,5)P₃ binding proteins [3] that may limit free binding/substrate sites available for PI3K and PTEN? Can their effect be quantified and modeled? Are PI3K and PTEN segregated upon intense receptor signaling? This segregation may relate to the need for establishing steep opposing gradients of PI(3,4,5)P₃ and PI(4,5)P₂ along the PM that may define polarity upon cell migration [143].

Significant questions about their allosteric regulation remain unanswered. Concerning PI3K α , how does the catalytic cycle close and PI3K α returns to its inactive state? What is its active conformation? If Δ ABD p110 α is indeed the active state of PI3K α , how does ABD domain interact again with p85 α (iSH2)? Does p85 α have a dual role, stabilizing the inactive state of PI3K α and at the same time homodimerizing and stabilizing PTEN on the membrane? p85 α /p110 and p85 α /PTEN coincide on RTKs? Are there any phospholipid recognition regions in the p85 α subunit? Concerning PTEN, how are PTEN dimers integrated in the conformational model of PTEN membrane interaction and catalysis?

Given the distinct PIP composition between PM and endosomes, the mechanisms controlling the balance between PI3K and PTEN activities in these prominent subcellular compartments also remain unexplored. So far, simulations and experiments have been biased towards a typical PM lipid composition. The different membrane interface in endosomal compartments may alter the rules of engagement. For PTEN specifically, PI(3)P seems to be an additional C2-directed docking site to endosomal membranes. Furthermore, it is intriguing to address whether PI3K/PTEN balance is affected by the exact coordinates of individual endosomal compartments, i.e. proximal to the PM versus distant ones, or by their maturation state, their shape, size and cargo content, and how these parameters affect the final output towards Akt signaling?

Finally, complexity of PI3K α and PTEN catalytic kinetics and interaction with membranes coupled with the inherent redundancy in PI(4,5)P₂ and PI(3,4,5)P₃ metabolism necessitates the use of innovative computational tools in parallel with current and future experimental approaches. Such computational tools ranging from predictive kinetic modelling [50,138], molecular dynamics simulations [86,87,90,125,177] to membrane interaction modelling and new cryo-EM structures will be of crucial importance in better understanding the interplay between these important signaling enzymes.

CRedit authorship contribution statement

Danai Maria Kotzampasi: Writing – original draft, Writing – review & editing, Visualization. **Kyriaki Premeti:** Writing – original draft, Writing – review & editing, Visualization. **Alexandra Papafotika:** Writing – original draft, Writing – review & editing, Visualization. **Vasiliki Syropoulou:** Writing – original draft, Writing – review & editing. **Savvas Christoforidis:** Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing. **Zoe Cournia:** Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing. **George Leondaritis:** Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was supported by the Hellenic Foundation for Research and Innovation (H.F.R.I.) under the “1st Call for H.F.R.I. Research Projects to support Faculty members and Researchers and the procurement of high-cost research equipment grant” (Project Number: 1780), awarded to Z. Cournia. This project has also received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956314.

Work in the group of G. Leontaritis is supported by project BIOMED-20 (MIS5047236) implemented under the Action “Reinforcement of the Research and Innovation Infrastructure” funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and European Regional Development Fund and grant 02667 funded by the Hellenic Foundation for Research and Innovation (H.F.R.I.) under the “2nd Call for H.F.R.I. Research Projects to support Faculty Members & Researchers”.

Work in the group of S. Christoforidis is supported by grants EDBM34, co-financed by Greece and the European Union (European Social Fund-ESF) in the context of the project MIS5004410, and project “BioImaging-GR: The Greek Research Infrastructure for the Imaging and Monitoring of Fundamental Biological Processes” (MIS 5002755).

Figures were created with BioRender.com and with PyMol.

References

- [1] Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. *Nat Rev Mol Cell Biol* 2018;19:281–96. <https://doi.org/10.1038/nrm.2017.138>.
- [2] Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. *Physiol Rev* 2013;93:1019–137. <https://doi.org/10.1152/physrev.00028.2012>.
- [3] Hammond GRV, Burke JE. Novel roles of phosphoinositides in signaling, lipid transport, and disease. *Curr Opin Cell Biol* 2020;63:57–67. <https://doi.org/10.1016/j.cceb.2019.12.007>.
- [4] Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. *Nature* 2006;443:651–7. <https://doi.org/10.1038/nature05185>.
- [5] Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. *Mol Biol Rep* 2020;47:4587–629. <https://doi.org/10.1007/s11033-020-05435-1>.
- [6] Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. *Sci Signal* 2011;4:re2. <https://doi.org/10.1126/scisignal.2002165>.
- [7] Tremel S, Ohashi Y, Morado DR, Bertram J, Perisic O, Brandt LTL, et al. Structural basis for VPS34 kinase activation by Rab1 and Rab5 on membranes. *Nat Commun* 2021;12:1564. <https://doi.org/10.1038/s41467-021-21695-2>.
- [8] Bayascas JR. PDK1: the major transducer of PI 3-kinase actions. *Curr Top Microbiol Immunol* 2010;346:9–29. https://doi.org/10.1007/82_2010_43.
- [9] Jiang Q, Zhang X, Dai X, Han S, Wu X, Wang L, et al. S6K1-mediated phosphorylation of PDK1 impairs AKT kinase activity and oncogenic functions. *Nat Commun* 2022;13:1548. <https://doi.org/10.1038/s41467-022-28910-8>.
- [10] Manning B, Tokar A. AKT/PKB signaling: navigating the network. *Cell* 2017;169:381–405. <https://doi.org/10.1016/j.cell.2017.04.001>.
- [11] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. *Cell* 2017;168:960–76. <https://doi.org/10.1016/j.cell.2017.02.004>.
- [12] Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. *Nat Rev Drug Discov* 2009;8:627–44. <https://doi.org/10.1038/nrd2926>.
- [13] Paddock MN, Field SJ, Cantley LC. Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance. *J Lipid Res* 2019;60:747–52. <https://doi.org/10.1194/jlr.S092130>.
- [14] Lee Y-R, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. *Nat Rev Mol Cell Biol* 2018;19:547–62. <https://doi.org/10.1038/s41580-018-0015-0>.
- [15] Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. *Cell* 2012;149:49–62. <https://doi.org/10.1016/j.cell.2012.02.030>.
- [16] Yehia L, Keel E, Eng C. The clinical spectrum of PTEN mutations. *Annu Rev Med* 2020;71:103–16. <https://doi.org/10.1146/annurev-med-052218-125823>.
- [17] Kreis P, Leondaritis G, Lieberam I, Eickholt BJ. Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders. *Front Mol Neurosci* 2014;7:23. <https://doi.org/10.3389/fnmol.2014.00023>.

- [18] Huang W, Jiang D, Wang X, Wang K, Sims CE, Allbritton NL, et al. Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives. *Anal Bioanal Chem* 2011;401:1881. <https://doi.org/10.1007/s00216-011-5257-z>.
- [19] Maheshwari S, Miller MS, O'Meally R, Cole RN, Amzel LM, Gabelli SB. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. *J Biol Chem* 2017;292:13541–50. <https://doi.org/10.1074/jbc.M116.772426>.
- [20] Knight ZA, Shokat KM. Features of selective kinase inhibitors. *Chem Biol* 2005;12:621–37. <https://doi.org/10.1016/j.chembiol.2005.04.011>.
- [21] Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, et al. Effects of oncogenic p110 α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. *Biochem J* 2007;409:519–24. <https://doi.org/10.1042/BJ20070681>.
- [22] Bolduc D, Rahdar M, Tu-Sekine B, Sivakumaren SC, Raben D, Amzel LM, et al. Phosphorylation-mediated PTEN conformational closure and deactivation revealed with protein semisynthesis. *ELife* 2013;2:e00691. <https://doi.org/10.7554/eLife.00691>.
- [23] Johnston SB, Raines RT. Conformational stability and catalytic activity of PTEN variants linked to cancers and autism spectrum disorders. *Biochemistry* 2015;54:1576–82. <https://doi.org/10.1021/acs.biochem.5b00028>.
- [24] McCONNACHIE G, Pass I, Walker SM, Downes CP. Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. *Biochem J* 2003;371:947–55. <https://doi.org/10.1042/bj20021848>.
- [25] Cullen PJ, Steinberg F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. *Nat Rev Mol Cell Biol* 2018;19:679–96. <https://doi.org/10.1038/s41580-018-0053-7>.
- [26] Sönnichsen B, De Renzis S, Nielsen E, Rietdorf J, Zerial M. Distinct membrane domains on endosomes in the recycling pathway visualized by multicolor imaging of Rab4, Rab5, and Rab11. *J Cell Biol* 2000;149:901–14. <https://doi.org/10.1083/jcb.149.4.901>.
- [27] Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. *Curr Opin Cell Biol* 2004;16:400–6. <https://doi.org/10.1016/j.cob.2004.06.005>.
- [28] Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. *Nat Rev Mol Cell Biol* 2009;10:609–22. <https://doi.org/10.1038/nrm2748>.
- [29] Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, et al. Oncogenes and signal transduction. *Cell* 1991;64:281–302. [https://doi.org/10.1016/0092-8674\(91\)90639-g](https://doi.org/10.1016/0092-8674(91)90639-g).
- [30] Christoforidis S, Miaczynska M, Ashman K, Wilm M, Zhao L, Yip SC, et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. *Nat Cell Biol* 1999;1:249–52. <https://doi.org/10.1038/12075>.
- [31] Wallroth A, Haucke V. Phosphoinositide conversion in endocytosis and the endolysosomal system. *J Biol Chem* 2018;293:1526–35. <https://doi.org/10.1074/jbc.R117.000629>.
- [32] Swanson JA, Araki N. Roles for 3' phosphoinositides in macropinocytosis. *Subcell Biochem* 2022;98:119–41. https://doi.org/10.1007/978-3-030-94004-1_7.
- [33] Boucrot E, Ferreira APA, Almeida-Souza L, Debarb S, Vallis Y, Howard G, et al. Endophilin marks and controls a clathrin-independent endocytic pathway. *Nature* 2015;517:460–5. <https://doi.org/10.1038/nature14067>.
- [34] Shin H-W, Hayashi M, Christoforidis S, Lacas-Gervais S, Hoepfner S, Wenk MR, et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. *J Cell Biol* 2005;170:607–18. <https://doi.org/10.1083/jcb.200505128>.
- [35] Buckles TC, Ohashi Y, Tremel S, McLaughlin SH, Pardon E, Steyaert J, et al. The G-protein Rab5A activates VPS34 complex II, a class III PI3K, by a dual regulatory mechanism. *Biophys J* 2020;119:2205–18. <https://doi.org/10.1016/j.bpj.2020.10.028>.
- [36] Zerial M, McBride H. Rab proteins as membrane organizers. *Nat Rev Mol Cell Biol* 2001;2:107–17. <https://doi.org/10.1038/35052055>.
- [37] Thapa N, Chen M, Horn HT, Choi S, Wen T, Anderson RA. Phosphatidylinositol-3-OH kinase signalling is spatially organized at endosomal compartments by microtubule-associated protein 4. *Nat Cell Biol* 2020;22:1357–70. <https://doi.org/10.1038/s41556-020-00596-4>.
- [38] Schenck A, Goto-Silva L, Collinet C, Rhinn M, Giner A, Habermann B, et al. The endosomal protein app1 mediates Akt substrate specificity and cell survival in vertebrate development. *Cell* 2008;133:486–97. <https://doi.org/10.1016/j.cell.2008.02.044>.
- [39] García-Regalado A, Guzmán-Hernández ML, Ramírez-Rangel I, Robles-Molina E, Balla T, Vázquez-Prado J, et al. G protein-coupled receptor-promoted trafficking of G β 1 γ 2 leads to AKT activation at endosomes via a mechanism mediated by G β 1 γ 2-Rab11a Interaction. *Mol Biol Cell* 2008;19:4188–200. <https://doi.org/10.1091/mbc.e07-10-1089>.
- [40] Thapa N, Horn HT, Anderson RA. Phosphoinositide spatially free AKT/PKB activation to all membrane compartments. *Adv Biol Regul* 2019;72:1–6. <https://doi.org/10.1016/j.abior.2019.04.002>.
- [41] Jethwa N, Chung GNC, Lete MG, Alonso A, Byrne RD, Calleja V, et al. Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway. *J Cell Sci* 2015;128:3456–65. <https://doi.org/10.1242/jcs.172775>.
- [42] Evans JH, Falke JJ. Ca²⁺ influx is an essential component of the positive-feedback loop that maintains leading-edge structure and activity in macrophages. *Proc Natl Acad Sci* 2007;104:16176–81. <https://doi.org/10.1073/pnas.0707719104>.
- [43] Basagiannis D, Zografou S, Murphy C, Fotsis T, Morbidelli L, Ziche M, et al. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation through macropinocytosis. *J Cell Sci* 2016;129:4091–104. <https://doi.org/10.1242/jcs.188219>.
- [44] Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. *Nature* 2010;465:487–91. <https://doi.org/10.1038/nature08995>.
- [45] Batrouni AG, Baskin JM. A MAP for PI3K activation on endosomes. *Nat Cell Biol* 2020;22:1292–4. <https://doi.org/10.1038/s41556-020-00597-3>.
- [46] Foley JF. MAPping PI3K signaling to endosomes. *Sci Signal* 2020;13:eabf7090. <https://doi.org/10.1126/scisignal.abf7090>.
- [47] Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isoforms in cell signalling and vesicle trafficking. *Nat Rev Mol Cell Biol* 2019;20:515–34. <https://doi.org/10.1038/s41580-019-0129-z>.
- [48] Sugiyama MG, Fairn GD, Antonescu CN. Akt-ing up just about everywhere: compartment-specific Akt activation and function in receptor tyrosine kinase signaling. *Front Cell Dev Biol* 2019;7. <https://doi.org/10.3389/fcell.2019.00070>.
- [49] Goulden BD, Pacheco J, Dull A, Zewe JP, Deiters A, Hammond GRV. A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product. *J Cell Biol* 2018;218:1066–79. <https://doi.org/10.1083/jcb.201809026>.
- [50] Malek M, Kielkowska A, Chessa T, Anderson KE, Barneda D, Pir P, et al. PTEN regulates PI(3,4)P2 signaling downstream of class I PI3K. *Mol Cell* 2017;68:566–580.e10. <https://doi.org/10.1016/j.molcel.2017.09.024>.
- [51] Naguib A, Benze G, Cho H, Zheng W, Tocij A, Elkayam E, et al. PTEN functions by recruitment to cytoplasmic vesicles. *Mol Cell* 2015;58:255–68. <https://doi.org/10.1016/j.molcel.2015.03.011>.
- [52] Shinde SR, Maddika S. PTEN regulates glucose transporter recycling by impairing SNX27 retromer assembly. *Cell Rep* 2017;21:1655–66. <https://doi.org/10.1016/j.celrep.2017.10.053>.
- [53] Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. *Nat Rev Cancer* 2011;11:289–301. <https://doi.org/10.1038/nrc3037>.
- [54] Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell* 2007;129:1261–74. <https://doi.org/10.1016/j.cell.2007.06.009>.
- [55] Koivusalo M, Welch C, Hayashi H, Scott CC, Kim M, Alexander T, et al. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. *J Cell Biol* 2010;188:547–63. <https://doi.org/10.1083/jcb.200908086>.
- [56] Robertson MJ, Deane FM, Robinson PJ, McCluskey A. Synthesis of dynole 34–2, Dynole 2–24 and Dyngo 4a for investigating dynamin GTPase. *Nat Protoc* 2014;9:851–70. <https://doi.org/10.1038/nprot.2014.046>.
- [57] Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. *Dev Cell* 2006;10:839–50. <https://doi.org/10.1016/j.devcel.2006.04.002>.
- [58] Ivanov AI. Pharmacological Inhibitors of Exocytosis and Endocytosis: Novel Bullets for Old Targets. In: Ivanov AI, editor. *Exocytosis Endocytosis*, vol. 1174, New York, NY: Springer New York; 2014, p. 3–18. https://doi.org/10.1007/978-1-4939-0944-5_1.
- [59] Ivanov AI. Pharmacological Inhibition of Endocytic Pathways: Is It Specific Enough to Be Useful? In: Ivanov AI, editor. *Exocytosis Endocytosis*, vol. 440, Totowa, NJ: Humana Press; 2008, p. 15–33. https://doi.org/10.1007/978-1-59745-178-9_2.
- [60] Basagiannis D, Zografou S, Galanopoulou K, Christoforidis S, Dynasore impairs VEGFR2 signalling in an endocytosis-independent manner. *Sci Rep* 2017;7:45035. <https://doi.org/10.1038/srep45035>.
- [61] Basagiannis D, Zografou S, Goula E, Gkeka D, Kolettas E, Christoforidis S. Chemical inhibitors of dynamin exert differential effects in VEGF signaling. *Cells* 2021;10:997. <https://doi.org/10.3390/cells10050997>.
- [62] Preta G, Cronin JG, Sheldon IM. Dynasore – not just a dynamin inhibitor. *Cell Commun Signal* 2015;13:24. <https://doi.org/10.1186/s12964-015-0102-1>.
- [63] Avinash P, Yann C, Jacques P, Daniela R. Dynamin inhibitors block mTORC1 activation by amino acids independently of dynamin. *J Cell Sci* 2017; jcs.211755. <https://doi.org/10.1242/jcs.211755>.
- [64] Park R, Shen H, Liu L, Liu X, Ferguson SM, De Camilli P. Dynamin triple knockout cells reveal off target effects of commonly used dynamin inhibitors. *J Cell Sci* 2013; jcs.138578. <https://doi.org/10.1242/jcs.138578>.
- [65] Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH, et al. Crystal structure and functional analysis of ras binding to its effector phosphoinositide 3-Kinase γ . *Cell* 2000;103:931–44. [https://doi.org/10.1016/S0092-8674\(00\)00196-3](https://doi.org/10.1016/S0092-8674(00)00196-3).
- [66] Zhang M, Jang H, Nussinov R. The structural basis for Ras activation of PI3K α lipid kinase. *Phys Chem Chem Phys* 2019;21:12021–8. <https://doi.org/10.1039/C9CP00101H>.
- [67] Echeverria I, Liu Y, Gabelli SB, Amzel LM. Oncogenic mutations weaken the interactions that stabilize the p110 α -p85 α heterodimer in phosphatidylinositol 3-kinase α . *FEBS J* 2015;282:3528–42. <https://doi.org/10.1111/febs.13365>.
- [68] Cheung LWT, Walkiewicz KW, Besong TMD, Guo H, Hawke DH, Arold ST, et al. Regulation of the PI3K pathway through a p85 α monomer-homodimer equilibrium. *ELife* 2015;4:e06866. <https://doi.org/10.7554/eLife.06866>.
- [69] Burke JE, Williams RL. Synergy in activating class I PI3Ks. *Trends Biochem Sci* 2015;40:88–100. <https://doi.org/10.1016/j.tibs.2014.12.003>.

- [70] Lee JY, Chiu Y-H, Asara J, Cantley LC. Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains. *Proc Natl Acad Sci U S A* 2011;108:14157–62. <https://doi.org/10.1073/pnas.1107747108>.
- [71] Ziemba BP, Burke JE, Masson G, Williams RL, Falke JJ. Regulation of PI3K by PKC and MARCKS: single-molecule analysis of a reconstituted signaling pathway. *Biophys J* 2016;110:1811–25. <https://doi.org/10.1016/j.bpj.2016.03.001>.
- [72] Ziemba BP, Falke JJ. A PKC-MARCKS-PI3K regulatory module links Ca²⁺ and PIP3 signals at the leading edge of polarized macrophages. *PLoS ONE* 2018;13:e0196678. <https://doi.org/10.1371/journal.pone.0196678>.
- [73] Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovich K, et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. *J Biol Chem* 2001;276:27455–61. <https://doi.org/10.1074/jbc.M100556200>.
- [74] Layton MJ, Saad M, Church NL, Pearson RB, Mitchell CA, Phillips WA. Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity. *BMC Biochem* 2012;13:30. <https://doi.org/10.1186/1471-2091-13-30>.
- [75] Mellor P, Furber LA, Nyarko JNK, Anderson DH. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking. *Biochem J* 2012;441:23–37. <https://doi.org/10.1042/BJ20111164>.
- [76] de la Cruz-Herrera CF, Baz-Martinez M, Lang V, El Motiam A, Barbazán J, Couceiro R, et al. Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation. *Oncogene* 2016;35:2873–80. <https://doi.org/10.1038/onc.2015.356>.
- [77] Castel P, Toska E, Engelman JA, Scaltriti M. The present and future of PI3K inhibitors for cancer therapy. *Nat Cancer* 2021;2:587–97. <https://doi.org/10.1038/s43018-021-00218-4>.
- [78] Burke JE, Williams RL. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). *Adv Biol Regul* 2013;53:97–110. <https://doi.org/10.1016/j.abr.2012.09.005>.
- [79] Buckles TC, Ziemba BP, Masson GR, Williams RL, Falke JJ. Single-molecule study reveals how receptor and Ras synergistically activate PI3Kα and PIP3 signaling. *Biophys J* 2017;113:2396–405. <https://doi.org/10.1016/j.bpj.2017.09.018>.
- [80] Miller MS, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, et al. Structural basis of nSH2 regulation and lipid binding in PI3Kα. *Oncotarget* 2014;5:5198–208. <https://doi.org/10.18632/oncotarget.2263>.
- [81] Zhang M, Jang H, Nussinov R. The mechanism of PI3Kα activation at the atomic level. *Chem Sci* 2019;10. <https://doi.org/10.1039/C8SC04498H>.
- [82] Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). *Proc Natl Acad Sci U S A* 2012;109:15259–64. <https://doi.org/10.1073/pnas.1205508109>.
- [83] Liu X, Yang S, Hart JR, Xu Y, Zou X, Zhang H, et al. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation. *Proc Natl Acad Sci U S A* 2021;118:e2109327118. <https://doi.org/10.1073/pnas.2109327118>.
- [84] Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc Natl Acad Sci U S A* 2005;102:18443–8. <https://doi.org/10.1073/pnas.0508988102>.
- [85] Mandelker D, Gabelli SB, Schmidt-Kittler O, Zhu J, Cheong I, Huang C-H, et al. A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane. *Proc Natl Acad Sci U S A* 2009;106:16996–7001. <https://doi.org/10.1073/pnas.0908444106>.
- [86] Gkeka P, Evangelidis T, Pavlaki M, Lazani V, Christoforidis S, Agianian B, et al. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. *PLoS Comput Biol* 2014;10:e1003895. <https://doi.org/10.1371/journal.pcbi.1003895>.
- [87] Gkeka P, Papafotika A, Christoforidis S, Cournia Z. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα. *J Phys Chem B* 2015;119:1002–16. <https://doi.org/10.1021/jp506423e>.
- [88] Ranga-Prasad H, Jenkins ML, Parson MA, Rathinaswamy MK, Burke JE. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. *2022:2022.04.05.487205*. <https://doi.org/10.1101/2022.04.05.487205>.
- [89] Siempelkamp BD, Rathinaswamy MK, Jenkins ML, Burke JE. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas. *J Biol Chem* 2017;292:12256–66. <https://doi.org/10.1074/jbc.M117.789263>.
- [90] Galdadas I, Gervasio FL, Cournia Z. Unravelling the effect of the E545K mutation on PI3Kα kinase. *Chem Sci* n.d.;11:3511–5. <https://doi.org/10.1039/c9sc05903b>.
- [91] Park M-J, Sheng R, Silkov A, Jung D-J, Wang Z-G, Xin Y, et al. SH2 domains serve as lipid binding modules for pTyr-signaling proteins. *Mol Cell* 2016;62:7–20. <https://doi.org/10.1016/j.molcel.2016.01.027>.
- [92] Redfern RE, Redfern D, Furgason MLM, Munson M, Ross AH, Gericke A. PTEN phosphatase selectively binds phosphoinositides and undergoes structural changes. *Biochemistry* 2008;47:2162–71. <https://doi.org/10.1021/bi702114w>.
- [93] Wei Y, Stec B, Redfield AG, Weerapana E, Roberts MF. Phospholipid-binding sites of phosphatase and tensin homolog (PTEN): exploring the mechanism of phosphatidylinositol 4,5-bisphosphate activation. *J Biol Chem* 2015;290:1592–606. <https://doi.org/10.1074/jbc.M114.588590>.
- [94] Lee J-O, Yang H, Georgescu M-M, Di Cristofano A, Maehama T, Shi Y, et al. Crystal structure of the PTEN tumor suppressor. *Cell* 1999;99:323–34. [https://doi.org/10.1016/S0092-8674\(00\)81663-3](https://doi.org/10.1016/S0092-8674(00)81663-3).
- [95] Shenoy S, Shekhar P, Heinrich F, Daou M-C, Gericke A, Ross AH, et al. Membrane association of the PTEN tumor suppressor: molecular details of the protein-membrane complex from SPR binding studies and neutron reflection. *PLoS ONE* 2012;7:e32591.
- [96] Masson GR, Perisic O, Burke JE, Williams RL. The intrinsically disordered tails of PTEN and PTEN-L have distinct roles in regulating substrate specificity and membrane activity. *Biochem J* 2016;473:135–44. <https://doi.org/10.1042/BJ20150931>.
- [97] Irvine WA, Flanagan JU, Allison JR. Computational prediction of amino acids governing protein-membrane interaction for the PIP3 cell signaling system. *Structure* 2019;27:371–380.e3. <https://doi.org/10.1016/j.str.2018.10.014>.
- [98] Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. *Proc Natl Acad Sci U S A* 2003;100:7491–6. <https://doi.org/10.1073/pnas.0932835100>.
- [99] Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. *Mol Cell Biol* 2000;20:5010–8. <https://doi.org/10.1128/MCB.20.14.5010-5018.2000>.
- [100] Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. *Cancer Res* 2000;60:7033–8.
- [101] Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan X-J, et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. *Proc Natl Acad Sci* 2000;97:4233–8. <https://doi.org/10.1073/pnas.97.8.4233>.
- [102] Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN Tail Acts as an inhibitory switch by preventing its recruitment into a protein complex. *J Biol Chem* 2001;276:48627–30. <https://doi.org/10.1074/jbc.C100556200>.
- [103] Lee S-R, Yang K-S, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2*. *J Biol Chem* 2002;277:20336–42. <https://doi.org/10.1074/jbc.M111899200>.
- [104] Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. *J Biol Chem* 2006;281:26562–8. <https://doi.org/10.1074/jbc.M605391200>.
- [105] Wang X, Trotman L, Koppie T, Alimonti A, Gao Z, Wang J, et al. NEDD4-1 Is a proto-oncogenic ubiquitin ligase for PTEN. *Cell* 2007;128:129–39. <https://doi.org/10.1016/j.cell.2006.11.039>.
- [106] Song MS, Salmena L, Pandolfi pp. The functions and regulation of the PTEN tumour suppressor. *Nat Rev Mol Cell Biol* 2012;13:283–96. <https://doi.org/10.1038/nrm3330>.
- [107] Cordier F, Chaffotte A, Terrien E, Préhaud C, Theillet F-X, Delepierre M, et al. Ordered phosphorylation events in two independent cascades of the PTEN C-Tail revealed by NMR. *J Am Chem Soc* 2012;134:20533–43. <https://doi.org/10.1021/ja310214g>.
- [108] Xu D, Yao Y, Jiang X, Lu L, Dai W. Regulation of PTEN stability and activity by PIK3. *J Biol Chem* 2010;285:39935–42. <https://doi.org/10.1074/jbc.M110.166462>.
- [109] Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. *J Biol Chem* 2001;276:993–8. <https://doi.org/10.1074/jbc.M009134200>.
- [110] Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3βeta. *J Biol Chem* 2005;280:35195–202. <https://doi.org/10.1074/jbc.M503045200>.
- [111] Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, et al. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. *Sci Signal* 2012;5. <https://doi.org/10.1126/scisignal.2002138>. ra18.
- [112] Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR. PTEN is destabilized by phosphorylation on Thr366. *Biochem J* 2007;405:439–44. <https://doi.org/10.1042/BJ20061837>.
- [113] Malaney P, Uversky VN, Davé V. Identification of intrinsically disordered regions in PTEN and delineation of its function via a network approach. *Methods San Diego Calif* 2015;77–78:69–74. <https://doi.org/10.1016/j.ymeth.2014.10.005>.
- [114] Shenoy SS, Nanda H, Lösche M. Membrane association of the PTEN tumor suppressor: Electrostatic interaction with phosphatidylserine-containing bilayers and regulatory role of the C-terminal tail. *J Struct Biol* 2012;180:394–408. <https://doi.org/10.1016/j.jsb.2012.10.003>.
- [115] Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. *Biochem J* 2004;379:301–7. <https://doi.org/10.1042/bj20031839>.
- [116] Jang H, Smith IN, Eng C, Nussinov R. The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane. *iScience* 2021;24. <https://doi.org/10.1016/j.isci.2021.102438>.
- [117] Kalli AC, Devaney I, Sansom MSP. Interactions of phosphatase and tensin homologue (PTEN) proteins with phosphatidylinositol phosphates: insights from molecular dynamics simulations of PTEN and voltage sensitive phosphatase. *Biochemistry* 2014;53:1724–32. <https://doi.org/10.1021/bi5000299>.

- [118] Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. *Proc Natl Acad Sci* 2009;106:480–5. <https://doi.org/10.1073/pnas.0811212106>.
- [119] Odriozola L, Singh G, Hoang T, Chan AM. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. *J Biol Chem* 2007;282:23306–15. <https://doi.org/10.1074/jbc.M611240200>.
- [120] Chen Z, Dempsey DR, Thomas SN, Hayward D, Bolduc DM, Cole PA. Molecular features of phosphatase and tensin homolog (PTEN) regulation by C-terminal phosphorylation. *J Biol Chem* 2016;291:14160–9. <https://doi.org/10.1074/jbc.M116.728980>.
- [121] Dempsey DR, Viennet T, Iwase R, Park E, Henriquez S, Chen Z, et al. The structural basis of PTEN regulation by multi-site phosphorylation. *Nat Struct Mol Biol* 2021;28:858–68. <https://doi.org/10.1038/s41594-021-00668-5>.
- [122] Nguyen H-N, Yang J-M, Afkari Y, Park BH, Sesaki H, Devreotes PN, et al. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. *Proc Natl Acad Sci* 2014;111. <https://doi.org/10.1073/pnas.1409433111>.
- [123] Nussinov R, Zhang M, Tsai C-J, Jang H. Phosphorylation and driver mutations in PI3K α and PTEN autoinhibition. *Mol Cancer Res MCR* 2021;19:543–8. <https://doi.org/10.1158/1541-7786.MCR-20-0818>.
- [124] Malaney P, Uversky VN, Davé V. The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy. *Mol Biosyst* 2013;9:2877–88. <https://doi.org/10.1039/c3mb70267g>.
- [125] Smith IN, Dawson JE, Krieger J, Thacker S, Bahar I, Eng C. Structural and dynamic effects of PTEN C-terminal tail phosphorylation. *Biophysics* 2022. <https://doi.org/10.1101/2022.04.16.488508>.
- [126] Miller SJ, Lou DY, Seldin DC, Lane WS, Neel BG. Direct identification of PTEN phosphorylation sites. *FEBS Lett* 2002;258:145–53. [https://doi.org/10.1016/S0014-5793\(02\)03274-X](https://doi.org/10.1016/S0014-5793(02)03274-X).
- [127] Zhang XC, Piccini A, Myers MP, Van Aelst L, Tonks NK. Functional analysis of the protein phosphatase activity of PTEN. *Biochem J* 2012;444:457–64. <https://doi.org/10.1042/BJ20120098>.
- [128] Lee C-U, Hahne G, Hanske J, Bange T, Bier D, Rademacher C, et al. Redox modulation of PTEN phosphatase activity by hydrogen peroxide and bisperoxovanadium complexes. *Angew Chem Int Ed Engl* 2015;54:13796–800. <https://doi.org/10.1002/anie.201506338>.
- [129] Papa A, Wan L, Bonora M, Salmena L, Song MS, Hobbs RM, et al. Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function. *Cell* 2014;157:595–610. <https://doi.org/10.1016/j.cell.2014.03.027>.
- [130] Heinrich F, Chakravarthy S, Nanda H, Papa A, Pandolfi PP, Ross AH, et al. The PTEN tumor suppressor forms homodimers in solution. *Struct Lond Engl* 1993;2015(23):1952–7. <https://doi.org/10.1016/j.str.2015.07.012>.
- [131] Lee Y-R, Chen M, Lee JD, Zhang J, Lin S-Y, Fu T-M, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. *Science* 2019;364. <https://doi.org/10.1126/science.aau0159>.
- [132] Cournia Z, Chatzigeorgoulas A. Allostery in membrane proteins. *Curr Opin Struct Biol* 2020;62:197–204. <https://doi.org/10.1016/j.sbi.2020.03.006>.
- [133] Chatzigeorgoulas A, Cournia Z. Rational design of allosteric modulators: challenges and successes. *WIREs Comput Mol Sci* 2021;11:e1529.
- [134] Chakrabarti M, Gabelli SB, Amzel LM. Allosteric activation of PI3K α results in dynamic access to catalytically competent conformations. *Structure* 2020;28:465–474.e5. <https://doi.org/10.1016/j.str.2020.01.010>.
- [135] Hon W-C, Berndt A, Williams RL. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. *Oncogene* 2012;31:3655–66. <https://doi.org/10.1038/onc.2011.532>.
- [136] Campbell RB, Liu F, Ross AH. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. *J Biol Chem* 2003;278:33617–20. <https://doi.org/10.1074/jbc.C300296200>.
- [137] Yoshioka D, Fukushima S, Koteishi H, Okuno D, Ide T, Matsuoka S, et al. Single-molecule imaging of PI(4,5)P₂ and PTEN in vitro reveals a positive feedback mechanism for PTEN membrane binding. *Commun Biol* 2020;3:92. <https://doi.org/10.1038/s42003-020-0818-3>.
- [138] Liu C, Deb S, Ferreira VS, Xu E, Baumgart T. Kinetics of PTEN-mediated PI(3,4,5)P₃ hydrolysis on solid supported membranes. *PLoS ONE* 2018;13:e0192667.
- [139] Lee AA, Huang WYC, Hansen SD, Kim NH, Alvarez S, Groves JT. Stochasticity and positive feedback enable enzyme kinetics at the membrane to sense reaction size. *Proc Natl Acad Sci* 2021;118:e2103626118. <https://doi.org/10.1073/pnas.2103626118>.
- [140] Fuchs J, Eickholt BJ, Leondaritis G. Harnessing PTEN's growth potential in neuronal development and disease. *Neurosci Insights* 2020;15:2633105520959056. <https://doi.org/10.1177/2633105520959056>.
- [141] Brosig A, Fuchs J, Ipek F, Kroon C, Schrötter S, Vadhvani M, et al. The axonal membrane protein PRG2 inhibits PTEN and directs growth to branches. *Cell Rep* 2019;29:2028–2040.e8. <https://doi.org/10.1016/j.celrep.2019.03.039>.
- [142] Gambardella L, Vermeren S. Molecular players in neutrophil chemotaxis—focus on PI3K and small GTPases. *J Leukoc Biol* 2013;94:603–12. <https://doi.org/10.1189/jlhb.1112564>.
- [143] Matsuoka S, Ueda M. Mutual inhibition between PTEN and PIP3 generates bistability for polarity in motile cells. *Nat Commun* 2018;9:4481. <https://doi.org/10.1038/s41467-018-06856-0>.
- [144] Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, et al. p85 associates with unphosphorylated PTEN and the PTEN-associated complex. *Mol Cell Biol* 2009;29:5377–88. <https://doi.org/10.1128/MCB.01649-08>.
- [145] Chaggar RB, Links PH, Pastor MC, Furber LA, Hawrysh AD, Chamberlain MD, et al. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. *Proc Natl Acad Sci* 2010;107:5471–6. <https://doi.org/10.1073/pnas.0908999107>.
- [146] Marshall JDS, Mellor P, Ruan X, Whitecross DE, Moore SA, Anderson DH. Insight into the PTEN - p85 α interaction and lipid binding properties of the p85 α BH domain. *Oncotarget* 2018;9:36975–92. <https://doi.org/10.18632/oncotarget.26432>.
- [147] Mellor P, Marshall JDS, Ruan X, Whitecross DE, Ross RL, Knowles MA, et al. Patient-derived mutations within the N-terminal domains of p85 α impact PTEN or Rab5 binding and regulation. *Sci Rep* 2018;8:7108. <https://doi.org/10.1038/s41598-018-25487-5>.
- [148] Tsolakos N, Durrant TN, Chessa T, Suire SM, Oxley D, Kulkarni S, et al. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. *Proc Natl Acad Sci* 2018;115:12176–81. <https://doi.org/10.1073/pnas.1803446115>.
- [149] Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, et al. PI3K-p110 α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85 α . *Proc Natl Acad Sci* 2017;114:7095–100. <https://doi.org/10.1073/pnas.1704706114>.
- [150] Hansen SD, Huang WYC, Lee YK, Bieling P, Christensen SM, Groves JT. Stochastic geometry sensing and polarization in a lipid kinase–phosphatase competitive reaction. *Proc Natl Acad Sci* 2019;116:15013–22. <https://doi.org/10.1073/pnas.1901744116>.
- [151] Wang J, Richards DA. Segregation of PIP2 and PIP3 into distinct nanoscale regions within the plasma membrane. *Biol Open* 2012;1:857–62. <https://doi.org/10.1242/bio.20122071>.
- [152] Wen Y, Vogt VM, Feigenson GW. PI(4,5)P₂ clustering and its impact on biological functions. *Annu Rev Biochem* 2021;90:681–707. <https://doi.org/10.1146/annurev-biochem-070920-094827>.
- [153] Myeong J, Park C-G, Suh B-C, Hille B. Compartmentalization of phosphatidylinositol 4,5-bisphosphate metabolism into plasma membrane liquid-ordered/raft domains. *Proc Natl Acad Sci* 2021;118:e2025343118. <https://doi.org/10.1073/pnas.2025343118>.
- [154] Gao X, Lowry PR, Zhou X, Depry C, Wei Z, Wong GW, et al. PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. *Proc Natl Acad Sci* 2011;108:14509–14. <https://doi.org/10.1073/pnas.1019386108>.
- [155] Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM. Rac1-mediated membrane raft localization of PI3K/p110 β is required for its activation by GPCRs or PTEN loss. *Life* 2016;5:e17635.
- [156] Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, et al. Discovery and SAR of Novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946). *ChemMedChem* 2016;11:1517–30. <https://doi.org/10.1002/cmdc.201600148>.
- [157] Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. *Int J Mol Sci* 2021;22:3464. <https://doi.org/10.3390/ijms22073464>.
- [158] Vanhaesebroeck B, Perry MWD, Brown JR, André F, Okkenhaug K. PI3K inhibitors are finally coming of age. *Nat Rev Drug Discov* 2021;20:741–69. <https://doi.org/10.1038/s41573-021-00209-1>.
- [159] Alpelisib MA. First global approval. *Drugs* 2019;79:1249–53. <https://doi.org/10.1007/s40265-019-01161-6>.
- [160] Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110 δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. *Blood* 2011;117:591–4. <https://doi.org/10.1182/blood-2010-03-275305>.
- [161] Burris HA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, et al. Umbralisib, a novel PI3K δ and casein kinase-1 ϵ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. *Lancet Oncol* 2018;19:486–96. [https://doi.org/10.1016/S1470-2045\(18\)30082-2](https://doi.org/10.1016/S1470-2045(18)30082-2).
- [162] Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, et al. PI3K- δ and PI3K- γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. *Chem Biol* 2013;20:1364–74. <https://doi.org/10.1016/j.chembiol.2013.09.017>.
- [163] Hanker AB, Kaklamani V, Arteaga CL. Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors. *Cancer Discov* 2019;9:482–91. <https://doi.org/10.1158/2159-8290.CD-18-1175>.
- [164] Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K α inhibitor. *Nature* 2015;518:240–4. <https://doi.org/10.1038/nature13948>.
- [165] Huw L-Y, O'Brien C, Pandita A, Mohan S, Spoerke JM, Lu S, et al. Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. *Oncogenesis* 2013;2:e83–e. <https://doi.org/10.1038/oncsis.2013.46>.
- [166] Corrà F, Agnoletto C, Minotti L, Baldassari F, Volinia S. The network of non-coding RNAs in cancer drug resistance. *Front Oncol* 2018;8:327. <https://doi.org/10.3389/fonc.2018.00327>.
- [167] Song KW, Edgar KA, Hanan EJ, Hafner M, Oeh J, Merchant M, et al. RTK-dependent inducible degradation of mutant PI3K α drives GDC-0077 (Inavolisib) efficacy. *Cancer Discov* 2022;12:204–19. <https://doi.org/10.1158/2159-8290.CD-21-0072>.

- [168] Arafeh R, Samuels Y. PIK3CA in cancer: the past 30 years. *Semin Cancer Biol* 2019;59:36–49. <https://doi.org/10.1016/j.semcancer.2019.02.002>.
- [169] Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. *Chem Sci* 2020;11:5855–65. <https://doi.org/10.1039/D0SC01676D>.
- [170] McLoughlin NM, Mueller C, Grossmann TN. The therapeutic potential of PTEN modulation: targeting strategies from gene to protein. *Cell Chem Biol* 2018;25:19–29. <https://doi.org/10.1016/j.chembiol.2017.10.009>.
- [171] Spinelli L, Lindsay YE, Leslie NR. PTEN inhibitors: an evaluation of current compounds. *Adv Biol Regul* 2015;57:102–11. <https://doi.org/10.1016/j.jbior.2014.09.012>.
- [172] Pulido R. PTEN inhibition in human disease therapy. *Mol Basel Switz* 2018;23:E285. <https://doi.org/10.3390/molecules23020285>.
- [173] Borges GA, Webber LP, Marques M, Guerra EN, Castilho RM, Squarize CH. Pharmacological PTEN inhibition: potential clinical applications and effects in tissue regeneration. *Regen Med* 2020;15:1329–44. <https://doi.org/10.2217/rme-2019-0065>.
- [174] Masson GR, Williams RL. Structural mechanisms of PTEN regulation. *Cold Spring Harb Perspect Med* 2020;10:. <https://doi.org/10.1101/cshperspect.a036152a036152>.
- [175] Ohtake Y, Hayat U, Li S. PTEN inhibition and axon regeneration and neural repair. *Neural Regen Res* 2015;10:1363. <https://doi.org/10.4103/1673-5374.165496>.
- [176] Knafo S, Sánchez-Puelles C, Palomer E, Delgado I, Draffin JE, Mingo J, et al. PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. *Nat Neurosci* 2016;19:443–53. <https://doi.org/10.1038/nn.4225>.
- [177] Leontiadou H, Galdadas I, Athanasiou C, Cournia Z. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. *Sci Rep* 2018;8:15544. <https://doi.org/10.1038/s41598-018-27044-6>.